Effect of Lugol's Solution in the Patients With Graves' Disease

Graves Disease Clinical Trial

Official title:

Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00432146
• Other study ID #: 2005/117
• Status: Completed
• Phase: N/A
• First received: February 5, 2007
• Last updated: October 17, 2008
• Start date: September 2005
• Est. completion date: September 2006

Study information

• Verified date: February 2007
• Source: Istanbul University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid gland vascularity, there is still no agreement on its effectiveness.

Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with Graves' disease according to the Lugol's solution treatment preoperatively.

Design: Retrospective clinical trial. Setting: A tertiary referral center. Method:

Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it.

Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.

Description:

Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 14 Years to 61 Years

Eligibility

Inclusion Criteria:

• Graves disease

Exclusion Criteria:

• Anticoagulant usage,

• Previous thyroid operation,

• Refused to participate in this study.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Graves Disease

Intervention

Drug:
• lugol's solution

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul University